Decision-Making During Percutaneous Coronary Intervention Guided by Optical Coherence Tomography: Insights From the LightLab Initiative.

"Disclosures Dr Bergmark received research grants (through the Brigham and Women’s Hospital) from Pfizer, Ionis, Quark, AstraZeneca/MedImmune, Amgen; Consulting/personal fees: Philips, Abbott Vascular, CSI, Abiomed, Servier, Janssen, Quark, Daiichi Sankyo. J. Buccola was employed by Abbott Vascular. Dr Wollmuth received honoraria from Abbott Vascular, Boston Scientific, Abiomed, Cardiovascular Systems, Inc, Philips, and Asahi Intecc. J. Spinelli was employed by Abbott Vascular. J. Meinen was employed by Abbott Vascular. Dr West was employed by Abbott Vascular. Dr Croce received grant support from Abbott, Takeda, Teleflex, CSI, honoraria from Abbott, Biotronik, Philips, Abiomed, CSI, Takeda and Cordis and is a major stock shareholder in Dyad Medical. Dr Bergmark, J.F. Kuder, and S.A. Murphy are members of the TIMI Study Group, which has received grant support from: Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc, Daiichi-Sankyo, Eisai, Intarcia, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc, Roche, Siemens Healthcare Diagnostics, Inc, The Medicines Company, Zora Biosciences."

"Sources of Funding The LightLab Initiative is a clinical program funded by Abbott Vascular."